Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 10/20 | 0.63 |
| ▸ | CDYL | Q9Y232 | 9/20 | 0.63 |
| ▸ | CBX7 | O95931 | 9/20 | 0.63 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 8/20 | 0.63 |
| ▸ | KMO | O15229 | 1/20 | 0.61 |
| ▸ | CD74 | P04233 | 2/20 | 0.54 |
| ▸ | MIF | P14174 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033665 | 1.00 | CDYL2 (0.63) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL16186523 | 0.84 | IDO1 (0.62) | KMO | |
| SCHEMBL20472305 | 0.84 | CBX7 (0.54) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL13099996 | 0.84 | CDYL2 (0.64) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL30660243 | 0.84 | CBX7 (0.54) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL2950965 | 0.83 | KMO (0.76) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL29957877 | 0.83 | KMO (0.76) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL29958210 | 0.82 | CDYL2 (0.69) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL27033393 | 0.82 | CDYL2 (0.69) | CDYL2CDYLCBX7CDY1; CDY1BKMO | |
| SCHEMBL5283365 | 0.82 | HPGD (0.62) | CDYL2CDYLCBX7CDY1; CDY1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CDYL2 3607/4885CDYL 3608/4885CBX7 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.